Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Voyager's Parkinson's Gene Therapy Poised For Pivotal Trial Exploration

Executive Summary

The Cambridge, Mass.-based biotech announced updated data from a Phase Ib trial of a gene therapy for Parkinson's disease, showing improvements in motor function and less time with dyskinesia.


Related Content

Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review
Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival
Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts